Apogee Therapeutics (APGE) Gains from Sales and Divestitures (2023 - 2026)
Apogee Therapeutics (APGE) reported Gains from Sales and Divestitures of $194060.0 for Q1 2026, little changed year-over-year from $194458.0 in Q1 2025, and down 75.05% quarter-over-quarter from $777736.0 in Q4 2025.
Apogee Therapeutics (APGE) Gains from Sales and Divestitures (2023 - 2026) Analysis & Trends
Apogee Therapeutics (APGE) has 4 years of Gains from Sales and Divestitures data on file, last reported at $194060.0 in Q1 2026.
- Gains from Sales and Divestitures for Q1 2026 came in at $194060.0, changed 0.2% year-over-year; the trailing twelve-month figure through Mar 2026 was $194060.0 (changed 0.2% YoY), and the FY2025 annual result was $777736.0, up 2059.9% from the prior year.
- Gains from Sales and Divestitures retreated to $194060.0 in Q1 2026 per APGE's latest filing, from $777736.0 in the prior quarter.
- Over five years, Gains from Sales and Divestitures peaked at $777736.0 in Q4 2025 and troughed at $36008.0 in Q4 2024.
- A 4-year average of $348797.6 and a median of $228677.0 in 2024 frame the typical range for Gains from Sales and Divestitures.
- On a YoY basis, Gains from Sales and Divestitures climbed as much as 2059.9% in 2025 and fell as far as 92.73% in 2025.
- A 4-year view of Gains from Sales and Divestitures shows it stood at $443831.0 in 2023, then tumbled by 91.89% to $36008.0 in 2024, then surged by 2059.9% to $777736.0 in 2025, then tumbled by 75.05% to $194060.0 in 2026.
- Business Quant data shows APGE's Gains from Sales and Divestitures at $194060.0 in Q1 2026, $777736.0 in Q4 2025, and $583341.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - |
| 10 | Apogee Therapeutics | 5.79 Bn | 4.73 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 194,060.00 |
| Mar 31, 2026 | 194,060.00 |
| Dec 31, 2025 | 777,736.00 |
| Dec 31, 2025 | 777,736.00 |
| Sep 30, 2025 | 583,341.00 |
| Sep 30, 2025 | 583,341.00 |
| Jun 30, 2025 | 37,213.00 |
| Jun 30, 2025 | 37,213.00 |
| Mar 31, 2025 | 194,458.00 |
| Mar 31, 2025 | 194,458.00 |
| Dec 31, 2024 | 36,008.00 |
| Dec 31, 2024 | 36,008.00 |
| Sep 30, 2024 | 706,614.00 |
| Sep 30, 2024 | 706,614.00 |
| Jun 30, 2024 | 512,153.00 |
| Jun 30, 2024 | 512,153.00 |
| Mar 31, 2024 | 228,677.00 |
| Mar 31, 2024 | 228,677.00 |
| Dec 31, 2023 | 443,831.00 |
| Dec 31, 2023 | 443,831.00 |